Condition: Huntington's Disease · Sponsor: Vaccinex Inc.
The purpose of this study is to evaluate the safety, tolerability, PK, and efficacy of Pepinemab in subjects with late prodromal and early manifest Huntington's disease.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| University of California, San Diego | La Jolla, California, United States | — |
| University of California San Francisco | San Francisco, California, United States | — |
| University of Colorado - Denver | Aurora, Colorado, United States | — |
| Georgetown University | Washington D.C., District of Columbia, United States | — |
| University of Florida Gainesville | Gainesville, Florida, United States | — |
| Emory University School of Medicine | Atlanta, Georgia, United States | — |
| Indiana University School of Medicine | Indianapolis, Indiana, United States | — |
| University of Iowa | Iowa City, Iowa, United States | — |
| University of Louisville | Louisville, Kentucky, United States | — |
| Johns Hopkins University | Baltimore, Maryland, United States | — |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | — |
+ 20 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02481674